Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Melanoma × Glucose × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Peritoneal Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Glioma 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

pembrolizumab 60 Nivolumab 38 Ipilimumab 25 trametinib 11 Specimen Handling 9 Cyclophosphamide 9 dabrafenib 8 Magnetic Resonance Spectroscopy 8 fludarabine 7 CTLA-4 Antigen 7 encorafenib 6 binimetinib 6 Radiosurgery 6 Interleukin-2 6 Biopsy 6 lenvatinib 5 fludarabine phosphate 5 atezolizumab 5 Radiotherapy 5 Introns 5 Cisplatin 5 durvalumab 4 dostarlimab 4 cobimetinib 4 Pemetrexed 4 Paclitaxel 4 Interferon alpha-2 4 Carboplatin 4 tocilizumab 3 tislelizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05933577 2025-09-24

V940-001

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡